Dicot
Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million
" A 96% subscription rate is a very good result in the current market and we feel great appreciation for everyone who participated and subscribed. I understand that with this we have received the second largest proceeds from an option exercise among listed Swedish small cap companies in the last six months. This again shows strong support from our shareholders and the great interest in Dicot Pharma and our drug development", comments Elin Trampe, CEO of Dicot Pharma.
Through the exercise of TO 6, Dicot Pharma will receive approximately SEK 43.8 million before issue costs. There are no costs for guarantee commitments as such agreements have not been entered into.
The exercise of the warrants changes the number of shares and share capital as follows:
|
|
Before TO 6 |
TO 6 |
After TO 6 |
|
Shares, # |
1,778,779,842 |
230,562,660 |
2,009,342,502 |
|
Share capital, SEK |
12,451,458.894 |
1,613,938.620 |
14,065,397.514 |
For existing shareholders who have not sold or exercised their warrants TO 6, the dilution amounts to approximately 11.5 percent.
Exercised warrants TO 6 have now been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares to ordinary shares is expected to take place around April 11, 2025.
Complete terms of the warrants and more information are available at www.dicotpharma.com.
| Datum | 2025-04-02, kl 08:30 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.